Abstract: A stable solution, cream, salve, or spray composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the treatment of vaginitis and endometriosis by reducing any of Candida, Actinobacillus actinomycetemcomitans, Pseudomonades, and Porphyromonas gingivalis present in the vagina or the uterus. The preferred concentration ranges are in the range of about 0.005% to about 2.0% of chlorine dioxide, and in the range of about 0.02% to about 3.0% of phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and a phosphate, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices brought about by any of leukoplakia, hairy leukoplakia, vaginitis, endometriosis, Candida Albicans, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Pseudomonades, Candida species, and leukoplakia vulvae. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: The invention describes an oral anti-acid paste comprising anti-acid compound in a slow releasing carrier medium which disperses the anti-acid, and releases the anti-acid from the paste upon contact with the aqueous media such as saliva. The paste can be used by placement in the mouth for slow release of the anti-acid into the saliva thereby contacting the mucosa of the esophagus to inhibit irritation to the mucosa due to excess acid.

Abstract: A bottled fluoridated water based drinking composition for the prevention and control of dental decay includes in a substantially non-fluoride reactive bottle containing therein at least one additional fluoride compound selected from a group consisting essentially sodium fluoride, potassium fluoride, magnesium fluoride, calcium fluoride, stannous fluoride, sodium monofluorophosphate, potassium monofluorophosphate and hydrogen fluoride and physiologically acceptable salts thereof, an acidifying compound which when dissolved in water will provide a weak acid and a weak base to initiate a buffering action and prevent the fluoride ions from going to completion and other selected formulating agents to provide protection of tooth surfaces from tooth caries disease and eventual tooth loss.

Abstract: A method for oxidatively consuming volatile sulfur compounds selected from the group consisting of dimethylsulfide, hydrogen sulfide, and methylmercaptan at the epithelial barrier of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices to maintain the epithelial barrier and reduce penetration of any of Candida, Actinobacillus actinomycetumcomitans, Pseudomonades, and Porphyromonas gingivalis, said method comprising the step of applying to the orifices a composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains chlorine dioxide in a concentration in the range of about 0.005% to about 2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodiuit phosphate, or sodium monofluorophosphate in a concentration in the range of about 0.02% to about 3.

Abstract: A stable solution, cream, salve, or spray composition containing chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are in the range of about 0.005% to about 2.0% chlorine dioxide, and in the range of about 0.02% to about 3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of about 6.0 to about 7.

Abstract: A method for preventing dental caries by administering fluoride and, at the same time controlling periodontal bone loss precipitated by the fluoride, by providing a combination of fluoride and NSAID is disclosed. Topical medicament compositions including NSAIDS and fluoride are also disclosed.

Abstract: This invention relates to a method and composition for inhibiting or destroying viruses or retroviruses in a mammalian host. The method comprises contacting the viruses or retroviruses with a composition. The composition comprises an active ingredient capable of inhibiting or destroying viruses or retroviruses, for example, a surfactant, and an activating ingredient capable of inhibiting or destroying one or more enzymes associated with viruses or retroviruses, for example, a fluorinated compound capable of releasing fluoride anions, and an excipient.

Abstract: A fluoride releasing dental composition comprising a polymer, a monomer and a metal fluoride. The polymer may be an acrylate polymer, a methacrylate polymer or a copolymer thereof. The monomer may be a monomeric heterocyclic acrylic ester, a monomeric heterocyclic methacrylic ester, a C.sub.3 -C.sub.16 alkyl acrylic ester or a C.sub.3 -C.sub.16 methacrylic ester. The metal fluoride is a nontoxic, biologically acceptable metal fluoride. In certain embodiments, the metal fluoride is sodium fluoride. The metal fluoride may comprise from approximately 0.1% to approximately 2% of the composition by weight.

Abstract: A stable solution, cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: A method for coating finely divided particles with one or more hydrophobic materials, such as waxes, in order to envelope each particle with a thin layer of material that entraps air adhering to the surface of the particle. Because of the entrapped air, the apparent density of the particles is decreased and their stability in aqueous suspensions is greatly improved. When applied to pesticides, this process produces mixtures that remain substantially in suspension for several hours after agitation, thus allowing more uniform and trouble-free application.

Abstract: Compositions for treating animals and surfaces infested with ectoparasites are provided for. The compositions comprise providing a solution consisting essentially of water and sea salt. The solution preferably includes a dissolved skin conditioner, preferably a natural skin conditioner, such as oat grains. The solution is applied to any animal, by dipping, spraying or in an aqueous-based carrier such as a shampoo, in an amount and for a period of time sufficient to deinfest the animal. The composition can be applied in dry form to carpets or lawns where animals lie to prevent infestation or reinfestation of the animal.

Abstract: A stable solution, cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.

Abstract: This invention relates to a method and composition for inhibiting or destroying viruses or retroviruses in a mammalian host. The method comprises contacting the viruses or retroviruses with a composition. The composition comprises an active ingredient capable of inhibiting or destroying viruses or retroviruses, for example, a surfactant, and an activating ingredient capable of inhibiting or destroying one or more enzymes associated with viruses or retroviruses, for example, a fluorinated compound capable of releasing fluoride anions, and an excipient.

Abstract: Methods for treating animals infested with ectoparasites are provided for. The methods comprise providing a solution consisting essentially of water and sea salt. The solution preferably includes a dissolved skin conditioner, preferably a natural skin conditioner, such as oat grains. The solution is applied to any animal, by dipping, spraying or in an aqueous-based carrier such as a shampoo, in an amount and for a period of time sufficient to deinfest the animal.

Abstract: A method is disclosed for controlling macroinvertebrates in aqueous systems, such as lakes, comprising adding to the aqueous system in recognized need of such control an effective controlling amount of an anionic toxicant containing the anion I.sup.- or F.sup.-, such as ethylenediamine (EDDI) or sodium fluoride (NaF).

Abstract: A transdermal fluoride medication for providing fluoride ion for the prevention and treatment of bone loss disease, which may have an estrogen-containing substance for not only treating hormonal imbalance but to obtain more advantageous use of the fluoride ion within the body. A transdermal enhancer is present. The preferred form is a transdermal patch containing sodium monofluorophosphate and further optionally including an estrogen-containing substance and a transdermal enhancer, which is adhesively attached on the skin of the patient for slow release of fluoride ion and, optionally, estrogen to the bloodstream of the patient. Up to ten percent of sodium fluoride and/or calcium can be added.

Abstract: An oral composition is provided that includes a peroxygen compound such as hydrogen peroxide, a fluoride-containing anticaries agent and a tin compound, especially stannous chloride. The tin compound stabilizes the peroxygen compound against decomposition that ordinarily would be induced by the presence of fluoride.

Abstract: A stable mouth wash or dentifrice composition containing stabilized chlorine dioxide and phosphates is disclosed for reducing the motility of and killing microbial pathogens. The preferred concentration ranges are between about 0.005%-0.5% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate retards escape of chlorine dioxide in the pH range (6.0 to 7.4) typically found in a mouth.

Abstract: Non-cariogenic sugar composition comprising 2 to 10 ppm fluoride, and preferably 50 to 400 mg/100 g each of calcium ion and phosphate (calculated as P) and 5 to 50 mg/100 g magnesium. The composition is made by blending a composition deficient in fluoride ion with a composition superabundant in fluoride ion, preferably obtained by selection of a superabundant fluoride ion containing fraction of cane sugar containing molasses, such as raw cane sugar, molasses, affination syrup, dried solids of molasses or of affination syrup or a blend thereof with refined sugar, or by evaporation of a mineral water to obtain a concentrate.

Abstract: Ammonium and alkali metal zinc lactate complexes used in oral compositions such as gingival and subgingival irrigating solutions, dentifrices, mouthwashes, and the like as well as in other preparations for treating oral lesions.

Abstract: A fluorosis-free ingestible fluoride ion-containing composition comprising a mixture of pharmaceutically acceptable fluoride and monofluorophosphate in a weight ratio to provide not more than about fifty percent, and preferably not more than about twenty-five percent, of available fluoride ion from the fluoride and the balance from the monofluorophosphate. By "fluorosis-free" composition is meant one which, when ingested, minimizes or obviates the occurrence of fluorosis which is a common effect when fluoride is ingested. The composition may contain additional pharmaceutically acceptable adjuvants, such as vitamins, coloring, flavoring, carriers, stabilizers, preservatives, medicants and the like, and may be in the form of a powder, tablet, capsule, pill or a liquid in a suitable ingestible carrier. Preferred compounds are alkali metal, ammonium and amine fluorides and monofluorophosphates. Most preferred compounds are sodium fluoride (NaF) and sodium monofluorophosphate (MFP), whose formula is Na.sub.2 FPO.

Abstract: A method is disclosed for remineralizing demineralized portions of teeth by treatment with a non-astringent composition containing about 10-20% xylitol, and at least one fluoride ion-providing compound in a total amount sufficient to provide about 150 ppm to about 1800 ppm of fluoride ions, with sodium fluoride providing a predominant proportion of such fluoride ions.

Abstract: The invention is directed to a composition and a method for preparing the same which composition inhibits or destroys unicellular living organisms. The composition is effective as a spermicide and also in combating sexually transmitted diseases and as an antiseptic agent. The composition of the invention comprises lithium and ionic or ionizable fluorine, for example, lithium fluoride. A suitable excipient such as KATHON may also be present. The invention may, for example, comprise lithium fluoride and a spermicidal agent, such as a quaternary ammonium compound, for example, benzalkonium chloride.

Abstract: A preservative-bearing pad and a method of using same to treat the interface between a railroad cross tie and tie plate. A sandwich of water-soluble active ingredient disposed between two layers of biodegradable hydrophilic backing is simply placed on the adzed portion of a cross tie prior to installation of the tie plate and rail during a rail laying or relaying operation.

Abstract: A medication for providing fluoride ion for the prevention and treatment of bone loss disease, together with an estrogen-containing substance for not only treating hormonal imbalance but to obtain more advantageous use of the fluoride ion within the body. The dosage is a lozenge, tablet or capsule containing from 20 to 100 milligrams of sodium monofluorophosphate and further including an estrogen-containing substance and a slow release mechanism for controlling release of the fluoride ion and estrogen over a period of from four to eight hours after swallowing. Up to ten percent of sodium fluoride and/or calcium can be added.

Abstract: The present invention discloses a method and aqueous composition for hardening and strengthening the keratinized appendages of mammals, and the nail keratin of humans, in particular. The aqueous keratin hardening and strengthening composition includes an effective amount of fluoride ion. The topical application of the fluoride ion is effected from an aqueous cosmetic vehicle capable of maintaining moist contact with the keratin for a sufficient period of time in the method practiced. Auxiliary keratin-strengthening agents are also disclosed.

Abstract: The inventive composition comprises an active ingredient, for example a quaternary ammonium compound, which active ingredient is capable of inhibiting or destroying a unicellular living organism, such as spermatazoa, bacteria or virus. The active ingredient is combined in a synergistic amount with an activating ingredient capable of inhibiting or destroying the enzymes associated with the unicellular organism. The activating ingredient may be capable of releasing fluoride ions, for example, an inorganic fluoride compound. The composition according to the invention is useful, for example, as a spermicide, or as an antibiotic, or as an anti-STD preparation for local or topical application.

Abstract: A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

Abstract: Oral compositions containing an acrylic acid polymer or copolymer, a soluble fluoride ion source and a strontium ion source are described herein.

Abstract: Dental compositions containing bicarbonate anion in combination with a monovalent anion such as fluoride, chloride or thiocyanate and methods of using them in anti-carogenic, antiplaque and antiperiodontopathic therapy are disclosed herein.

Abstract: A medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge, tablet or capsule containing from 20 to 100 milligrams of sodium monofluorophosphate and further includes a slow release mechanism for controlling release of the fluoride ion over a period of up to eight hours after swallowing. Up to ten percent of sodium fluoride can be added.

Abstract: The present invention relates to pharmaceutical products containing a mixture of benzoic acid, phenol and an alkali fluoride, in an aqueous or aqueous-alcohol solution, optionally in the presence of other usual additives for pharmaceutical preparations, in liquid or semi-liquid form, for the control of diseases in the human caused by herpes virus, and to methods for the topical treatment with these products of herpes simplex efflorescences in the human.

Abstract: A bioadhesive extruded single or multi-layered thin film, especially useful in intra-oral controlled-releasing delivery, having a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]. .Iadd.20-92.Iaddend.% by weight of a hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer such as ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a medicament, e.g. anesthetics, analgesics, anticaries agents, anti-inflammatories, antihistamines, antibiotics, antibacterials, fungistats, etc.